Ivan M Lieberburg's Net Worth
$150 Million
Who is Ivan M Lieberburg?
Ivan M Lieberburg has an estimated net worth of $150 Million. This is based on reported shares across multiple companies, which include Mirati Therapeutics, Inc., CATASYS, INC., Adamas Pharmaceuticals Inc, and ARADIGM CORP.
SEC CIK
Ivan M Lieberburg's CIK is 0001266427
Past Insider Trading and Trends
2017 was Ivan M Lieberburg's most active year for acquiring shares with 7 total transactions. Ivan M Lieberburg's most active month to acquire stocks was the month of May. 2015 was Ivan M Lieberburg's most active year for disposing of shares, totalling 12 transactions. Ivan M Lieberburg's most active month to dispose stocks was the month of September. 2017 saw Ivan M Lieberburg paying a total of $17,106,197.52 for 2,961,962 shares, this is the most they've acquired in one year. In 2020 Ivan M Lieberburg cashed out on 800,006 shares for a total of $83,040,276.71, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Mirati Therapeutics, Inc. (MRTX) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +10.47% | 211.44K |
$181.15 | -$72,460,293.56 | 2.23M |
Mar 5
| |||
Form 4
|
—
|
0
|
$207.99 | -$80,800,259.91 | 3.42M |
Oct 30
| |||
Form 4
| +18.19% | 267.97K |
$7.86 | $2,106,212.76 | 1.74M |
Oct 3
| |||
Form 4
| +24.10% | 286.16K |
$5.60 | $1,602,512.80 | 1.47M |
Jan 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CATASYS, INC. (OTRK) Snapshot price: $0.18
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 4
| +3,900.36% | 43.33K |
$4.50 | $194,998.50 | 44.44K |
Dec 14 - Dec 15
| |||
Form 4
|
∞
| 1.11K |
$4.50 | $4,999.50 | 1.11K |
Dec 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Adamas Pharmaceuticals Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +10.42% | 5K |
—
|
—
| 53K |
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
| -5.88% | -3.00K |
$16.23 | -$48,690.00 | 48K |
Scheduled
|
Dec 7
| ||
Form 4
| -5.56% | -3.00K |
$15.00 | -$45,000.00 | 51K |
Scheduled
|
Nov 2
| ||
Form 4
| -5.26% | -3.00K |
$16.75 | -$50,250.00 | 54K |
Scheduled
|
Oct 5
| ||
Form 4
| -5.00% | -3.00K |
$19.13 | -$57,390.00 | 57K |
Scheduled
|
Sep 8
| ||
Form 4
| -4.76% | -3.00K |
$24.51 | -$73,530.00 | 60K |
Scheduled
|
Aug 3
| ||
Form 4
| -4.55% | -3.00K |
$25.91 | -$77,730.00 | 63K |
Scheduled
|
Jul 6
| ||
Form 4
| -4.35% | -3.00K |
$17.93 | -$53,790.00 | 66K |
Scheduled
|
Jun 1
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
| -4.17% | -3.00K |
$16.82 | -$50,460.00 | 69K |
Scheduled
|
May 4
| ||
Form 4
| -4.00% | -3.00K |
$17.44 | -$52,320.00 | 72K |
Scheduled
|
Apr 6
| ||
Form 4
| -3.85% | -3.00K |
$16.97 | -$50,910.00 | 75K |
Scheduled
|
Mar 2
| ||
Form 4
| -3.70% | -3.00K |
$16.77 | -$50,310.00 | 78K |
Scheduled
|
Feb 2
| ||
Form 4
| -3.57% | -3.00K |
$17.59 | -$52,770.00 | 81K |
Scheduled
|
Jan 5
| ||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARADIGM CORP No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||